Drugs based on small molecules
AlzeCure’s drug candidates are based on small molecules, which offer several advantages over biologics:
- Small molecules can be designed to provide better permeability across the blood-brain barrier than biologics, and are therefore well suited for treatment of diseases of the brain.
- Small molecules can be given as oral treatment, in tablet form, which is both convenient and costeffectively advantageous for the patient compared to invasive intravenous injections, which often have to be administered by care providers.
- Small molecules are less expensive to produce than biologics, which could potentially provide pricerelated advantages, for example with respect to long-term treatment of chronic diseases.